Effects of Allocating Livers for Transplantation Based on Model for End-Stage Liver Disease-Sodium Scores on Patient Outcomes

被引:74
|
作者
Nagai, Shunji [1 ]
Chau, Lucy C. [1 ]
Schilke, Randolph E. [1 ]
Safwan, Mohamed [1 ]
Rizzari, Michael [1 ]
Collins, Kelly [1 ]
Yoshida, Atsushi [1 ]
Abouljoud, Marwan S. [1 ]
Moonka, Dilip [2 ]
机构
[1] Henry Ford Hosp, Transplant & Hepatobiliary Surg, 2799 W Grand Blvd,CFP 2, Detroit, MI 48202 USA
[2] Henry Ford Hosp, Gastroenterol, Detroit, MI 48202 USA
关键词
Hyponatremia; Waitlist Mortality; Survival Benefit; United Network for Organ Sharing; SERUM SODIUM; SHARE; 35; SURVIVAL BENEFIT; MELD-NA; MORTALITY; IMPACT; RISK;
D O I
10.1053/j.gastro.2018.07.025
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: The Model for End-stage Liver Disease and Sodium (MELD-Na) score was introduced for liver allocation in January 2016. We evaluated the effects of liver allocation, based on MELD-Na score, on waitlist and post-transplantation outcomes. METHODS: We examined 2 patient groups from the United Network for Organ Sharing registry; the MELD-period group was composed of patients who were registered as transplant candidates from June 18, 2013 through January 10, 2016 (n = 18,850) and the MELD-Na period group was composed of patients who were registered from January 11, 2016 through September 30, 2017 (n = 14,512). We compared waitlist and post-transplantation outcomes and association with serum sodium concentrations between groups. RESULTS: Mortality within 90 days on the liver waitlist decreased (hazard ratio [HR] 0.738, P<.001) and transplantation probability increased significantly (HR 1.217, P = <.001) in the MELD-Na period. Although mild, moderate, and severe hyponatremia (130-134, 125129, and <125 mmol/L) were independent risk factors for waitlist mortality in the MELD period (HR 1.354, 1.762, and 2.656; P<.001, P<.001, and P<.001, respectively) compared with the reference standard (135-145 mmol/L), these adverse outcomes were decreased in the MELD-Na period (HR 1.092, 1.271 and 1.374; P=.27, P=.018, and P=.037, respectively). The adjusted survival benefit of transplant recipients vs patients placed on the waitlist in the same score categories was definitive for patients with MELD-Na scores of 21-23 in the MELD-Na era (HR 0.336, P<.001) compared with MELD scores of 15-17 in the MELD era (HR 0.365, P<.001). CONCLUSIONS: Liver allocation based on MELD-Na score successfully improved waitlist outcomes and provided significant benefit to hyponatremic patients. Given the discrepancy in transplantation survival benefit, the current rules for liver allocation might require revision.
引用
收藏
页码:1451 / +
页数:15
相关论文
共 50 条
  • [41] Outcomes of Liver Transplantation for Porto-Pulmonary Hypertension in Model for End-Stage Liver Disease Era
    Salgia, Reena J.
    Goodrich, Nathan P.
    Simpson, Heather
    Merion, Robert M.
    Sharma, Pratima
    DIGESTIVE DISEASES AND SCIENCES, 2014, 59 (08) : 1976 - 1982
  • [42] Outcomes for patients listed for liver transplantation with a low Model for End-Stage Liver Disease (MELD) score
    Mufti, Arjmand R.
    Tanriover, Bekir
    Singal, Amit G.
    Marrero, Jorge A.
    HEPATOLOGY, 2016, 64 : 697A - 698A
  • [43] Outcomes of Liver Transplantation for Porto-Pulmonary Hypertension in Model for End-Stage Liver Disease Era
    Reena J. Salgia
    Nathan P. Goodrich
    Heather Simpson
    Robert M. Merion
    Pratima Sharma
    Digestive Diseases and Sciences, 2014, 59 : 1976 - 1982
  • [44] The predictive value of MELDNa (model for end-stage liver disease-sodium) and mean platelet volume/platelet count for patients' 30-day mortality after liver transplantation
    Bayrak, Vecihe
    Gurkok, Mehmet Cagatay
    Aydemir, Ferhan Demirer
    Ergun, Bisar
    Egeli, Tufan
    Durukan, Nurcan Senturk
    Unek, Tarkan
    Gokmen, Necati
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2022, 8 (02) : 111 - 117
  • [45] Risk factors for pre-transplantation bacteremia in adults with end-stage liver disease: Effects on outcomes of liver transplantation
    Lee, Ing-Kit
    Chang, Po-Hsun
    Li, Wei-Feng
    Yeh, Cheng-His
    Yin, Shih-Min
    Lin, Yu-Cheng
    Tzeng, Wei-Juo
    Liu, Yu-Ling
    Wang, Chih-Chi
    Chen, Chao-Long
    Lin, Chih-Che
    Chen, Yi-Chun
    CLINICAL TRANSPLANTATION, 2024, 38 (01)
  • [46] Could tenofovir modify the model end-stage liver disease (MELD) score in patients with end-stage liver disease eligible for liver transplantation?
    Bruno, Raffaele
    Sacchi, Paolo
    Filice, Gaetano
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 45 (01) : 123 - 123
  • [47] Impact of Creatinine Values on Model for End-Stage Liver Disease (MELD) Scores in Male and Female Candidates for Liver Transplantation
    Mariante Neto, Guilherme
    Brandao, Ajacio M.
    Marroni, Caroline P.
    Marroni, Claudio A.
    Zanotelli, Maria Lucia
    Cantisani, Guido P. C.
    LIVER TRANSPLANTATION, 2012, 18 : S167 - S167
  • [48] Should Liver Transplantation in Patients with Model for End-Stage Liver Disease Scores ≤ 14 Be Avoided? A Decision Analysis Approach
    Perkins, James D.
    Halldorson, Jeffrey B.
    Bakthavatsalam, Ramasamy
    Fix, Oren K.
    Carithers, Robert L., Jr.
    Reyes, Jorge D.
    LIVER TRANSPLANTATION, 2009, 15 (02) : 242 - 254
  • [49] Liver Transplantation in Recipients With High Model for End-stage Liver Disease Score
    Gonzalez Martinez, S.
    Molina Raya, A.
    Becerra Massare, A.
    Muffak Granero, K.
    Villegas Herrera, T.
    Villar del Moral, J. M.
    Fundora Suarez, Y.
    TRANSPLANTATION PROCEEDINGS, 2018, 50 (02) : 595 - 597
  • [50] Model for end-stage liver disease limbo, model for end-stage liver disease purgatory, and the dilemma of treating hepatitis C in patients awaiting liver transplantation
    Carrion, Andres F.
    Khaderi, Saira A.
    Sussman, Norman L.
    LIVER TRANSPLANTATION, 2016, 22 (03) : 279 - 280